Citi raised the firm’s price target on Stryker (SYK) to $455 from $443 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker announces FDA 510(k) clearance for OptaBlate
- Stryker Shareholders Approve Amendments at Annual Meeting
- Stryker’s Strategic Moves and Strong Financial Outlook Justify Buy Rating with $435 Price Target
- Stryker price target raised to $400 from $390 at Truist
- Stryker price target raised to $450 from $440 at Bernstein